Galecto Inc
(NAS:GLTO)
$
0.5151
-0.0219 (-4.08%)
Market Cap: 13.97 Mil
Enterprise Value: -13.05 Mil
PE Ratio: 0
PB Ratio: 0.50
GF Score: 38/100 Galecto Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022 / 08:25AM GMT
Release Date Price:
$1.75
(-2.78%)
Amalia Veerabahu
Jefferies LLC - (Trades, Portfolio) LLC - Analyst
Good morning, and welcome to the Jefferies Healthcare Conference. I'm Amalia from the Jefferies healthcare investment banking team. And I'm delighted to introduce our next presenter: Hans Schambye, CEO of Galecto. Thank you.
Hans Schambye
Galecto, Inc. - CEO
Thanks a lot, Amalia. I'm very glad to be here presenting Galecto. So I will be making forward-looking statements. You can see this statement on our website. Galecto is all about developing treatments for oncology and fibrosis. We are targeting two different proteins, galectin-3 and LOXL2, that play a very central role in what's happening in the tumor microenvironment and in scar tissue, which fibrosis is.
We have developed very
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot